CYP2A13: Difference between revisions

Jump to navigation Jump to search
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
Line 59: Line 59:


==References==
==References==
{{reflist}}
{{reflist|2}}
==Further reading==
==Further reading==
{{refbegin | 2}}
{{refbegin | 2}}

Revision as of 15:15, 4 September 2012


Cytochrome P450, family 2, subfamily A, polypeptide 13
PDB rendering based on 1z10.
Identifiers
Symbols CYP2A13 ; CYP2A; CPAD
External IDs Template:OMIM5 Template:MGI HomoloGene85917
RNA expression pattern
More reference expression data
Orthologs
Template:GNF Ortholog box
Species Human Mouse
Entrez n/a n/a
Ensembl n/a n/a
UniProt n/a n/a
RefSeq (mRNA) n/a n/a
RefSeq (protein) n/a n/a
Location (UCSC) n/a n/a
PubMed search n/a n/a

WikiDoc Resources for CYP2A13

Articles

Most recent articles on CYP2A13

Most cited articles on CYP2A13

Review articles on CYP2A13

Articles on CYP2A13 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on CYP2A13

Images of CYP2A13

Photos of CYP2A13

Podcasts & MP3s on CYP2A13

Videos on CYP2A13

Evidence Based Medicine

Cochrane Collaboration on CYP2A13

Bandolier on CYP2A13

TRIP on CYP2A13

Clinical Trials

Ongoing Trials on CYP2A13 at Clinical Trials.gov

Trial results on CYP2A13

Clinical Trials on CYP2A13 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on CYP2A13

NICE Guidance on CYP2A13

NHS PRODIGY Guidance

FDA on CYP2A13

CDC on CYP2A13

Books

Books on CYP2A13

News

CYP2A13 in the news

Be alerted to news on CYP2A13

News trends on CYP2A13

Commentary

Blogs on CYP2A13

Definitions

Definitions of CYP2A13

Patient Resources / Community

Patient resources on CYP2A13

Discussion groups on CYP2A13

Patient Handouts on CYP2A13

Directions to Hospitals Treating CYP2A13

Risk calculators and risk factors for CYP2A13

Healthcare Provider Resources

Symptoms of CYP2A13

Causes & Risk Factors for CYP2A13

Diagnostic studies for CYP2A13

Treatment of CYP2A13

Continuing Medical Education (CME)

CME Programs on CYP2A13

International

CYP2A13 en Espanol

CYP2A13 en Francais

Business

CYP2A13 in the Marketplace

Patents on CYP2A13

Experimental / Informatics

List of terms related to CYP2A13


Cytochrome P450, family 2, subfamily A, polypeptide 13, also known as CYP2A13, is a human gene.[1]

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. Although its endogenous substrate has not been determined, it is known to metabolize 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a major nitrosamine specific to tobacco. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.[1]

References

  1. 1.0 1.1 "Entrez Gene: CYP2A13 cytochrome P450, family 2, subfamily A, polypeptide 13".

Further reading

  • Fernandez-Salguero P, Gonzalez FJ (1995). "The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis". Pharmacogenetics. 5 Spec No: S123–8. PMID 7581481.
  • Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily". Xenobiotica. 28 (12): 1129–65. PMID 9890157.
  • Nelson DR, Zeldin DC, Hoffman SM; et al. (2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics. 14 (1): 1–18. PMID 15128046.
  • Fernandez-Salguero P, Hoffman SM, Cholerton S; et al. (1995). "A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles". Am. J. Hum. Genet. 57 (3): 651–60. PMID 7668294.
  • Hoffman SM, Fernandez-Salguero P, Gonzalez FJ, Mohrenweiser HW (1996). "Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19". J. Mol. Evol. 41 (6): 894–900. PMID 8587134.
  • Koskela S, Hakkola J, Hukkanen J; et al. (1999). "Expression of CYP2A genes in human liver and extrahepatic tissues". Biochem. Pharmacol. 57 (12): 1407–13. PMID 10353262.
  • Su T, Bao Z, Zhang QY; et al. (2000). "Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone". Cancer Res. 60 (18): 5074–9. PMID 11016631.
  • Zhang X, Su T, Zhang QY; et al. (2002). "Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant". J. Pharmacol. Exp. Ther. 302 (2): 416–23. PMID 12130698.
  • Saito S, Iida A, Sekine A; et al. (2003). "Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population". J. Hum. Genet. 48 (5): 249–70. doi:10.1007/s10038-003-0021-7. PMID 12721789.
  • Wang H, Tan W, Hao B; et al. (2004). "Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK". Cancer Res. 63 (22): 8057–61. PMID 14633739.
  • Cauffiez C, Lo-Guidice JM, Quaranta S; et al. (2004). "Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility". Biochem. Biophys. Res. Commun. 317 (2): 662–9. doi:10.1016/j.bbrc.2004.03.092. PMID 15063809.
  • Cheng XY, Chen GL, Zhang WX; et al. (2004). "Arg257Cys polymorphism of CYP2A13 in a Chinese population". Clin. Chim. Acta. 343 (1–2): 213–6. doi:10.1016/j.cccn.2004.01.017. PMID 15115698.
  • He XY, Shen J, Ding X; et al. (2005). "Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen". Drug Metab. Dispos. 32 (12): 1516–21. doi:10.1124/dmd.104.001370. PMID 15333516.
  • Fujieda M, Yamazaki H, Kiyotani K; et al. (2005). "Eighteen novel polymorphisms of the CYP2A13 gene in Japanese". Drug Metab. Pharmacokinet. 18 (1): 86–90. PMID 15618722.
  • Smith BD, Sanders JL, Porubsky PR; et al. (2007). "Structure of the human lung cytochrome P450 2A13". J. Biol. Chem. 282 (23): 17306–13. doi:10.1074/jbc.M702361200. PMID 17428784.


Template:WH Template:WikiDoc Sources